Stereotaxis Q4 2023 Earnings Report

Stereotaxis EPS Results

• Actual EPS: -$0.07
• Consensus EPS: -$0.07
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Stereotaxis Revenue Results

• Actual Revenue: $4.57 million
• Expected Revenue: $7.55 million
• Beat/Miss: Missed by -$2.98 million
• YoY Revenue Growth: N/A

Stereotaxis Announcement Details

• Quarter: Q4 2023
• Date: 3/4/2024
• Time: N/A

Stereotaxis (NYSEAMERICAN:STXS) designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.